<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01708720</url>
  </required_header>
  <id_info>
    <org_study_id>NVI-256A</org_study_id>
    <secondary_id>2010-024581-22</secondary_id>
    <nct_id>NCT01708720</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults</brief_title>
  <official_title>Safety and Immunogenicity of Sabin-IPV and Adjuvanted Sabin-IPV in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pauline Verdijk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute for Public Health and the Environment (RIVM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether the new inactivated polio vaccine that is&#xD;
      based on attenuated poliovirus strains is safe and to evaluate the immune response in healthy&#xD;
      adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to assess the safety and immunogenicity of Sabin-IPV and adjuvanted&#xD;
      Sabin-IPV produced with the production process set up for technology transfer by the National&#xD;
      Institute for Public Health and the Environment (RIVM, formerly the Netherlands Vaccine&#xD;
      Institute (NVI).&#xD;
&#xD;
        -  The primary objective is to evaluate safety (local and systemic reactions) of&#xD;
           intramuscular injection with Sabin-IPV and adjuvanted Sabin-IPV in healthy adults (first&#xD;
           in human).&#xD;
&#xD;
        -  The secondary objective is to evaluate immunogenicity of Sabin-IPV and adjuvanted&#xD;
           Sabin-IPV in healthy immunized adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse reactions following vaccination</measure>
    <time_frame>4 days or until adverse reactions have resolved</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of virus neutralizing titers in serum</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Sabin-IPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvanted Sabin-IPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPV</intervention_name>
    <arm_group_label>IPV</arm_group_label>
    <other_name>Inactivated poliomyelitis vaccine</other_name>
    <other_name>Inactivated polio vaccine</other_name>
    <other_name>Inactivated poliovirus vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sabin-IPV</intervention_name>
    <arm_group_label>Sabin-IPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvanted Sabin-IPV</intervention_name>
    <arm_group_label>Adjuvanted Sabin-IPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 49, inclusive at the time of enrolment&#xD;
&#xD;
          -  in good health as determined by the outcome of medical history, physical examination&#xD;
             screening/baseline labs and clinical judgment of the investigator&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Must have received polio vaccinations with OPV according to the Polish National&#xD;
             Immunization Program as a child based on vaccination cards or information given by&#xD;
             subjects during interview with investigator&#xD;
&#xD;
          -  Preferred: number (and date) of polio vaccinations known&#xD;
&#xD;
          -  Willingness and ability to adhere to the study regimen&#xD;
&#xD;
          -  Having a signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IPV or OPV booster dose after the age of 12 years&#xD;
&#xD;
          -  Positive for HIV, Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Known or suspected allergy against any of the vaccine components&#xD;
&#xD;
          -  History of unusual or severe reactions to any previous vaccination&#xD;
&#xD;
          -  Known or suspected disease or use of medication that may influence the immune system&#xD;
&#xD;
          -  Known or suspected immune deficiency&#xD;
&#xD;
          -  Systemic treatment with corticosteroids within one month before screening&#xD;
&#xD;
          -  Administration of plasma (including immunoglobulins) or blood products three months&#xD;
             prior to the study&#xD;
&#xD;
          -  Blood donation within one month before screening&#xD;
&#xD;
          -  Any vaccination within three months before screening and during the study until the&#xD;
             last visit&#xD;
&#xD;
          -  History of any neurological disorder including epilepsy or febrile seizures&#xD;
&#xD;
          -  Evidence of excessive alcohol use or drug use&#xD;
&#xD;
          -  Any infectious disease at the time of screening and/or inclusion&#xD;
&#xD;
          -  Participation in another clinical trial within three months before screening&#xD;
&#xD;
          -  Abnormal pre-treatment laboratory parameters which are clinically relevant according&#xD;
             to the investigator&#xD;
&#xD;
          -  Bleeding disorders or the usage of anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pauline Verdijk, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute for Public Health and the Environment</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Szpital Internistyczny cetrum Badan Farmakologii Klinicznej Monipol Sp. z o.o.</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011 Sep 22;29(41):7188-96. doi: 10.1016/j.vaccine.2011.05.079. Epub 2011 Jun 7.</citation>
    <PMID>21651934</PMID>
  </reference>
  <reference>
    <citation>Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines. 2011 May;10(5):635-44. doi: 10.1586/erv.11.51. Review.</citation>
    <PMID>21604984</PMID>
  </reference>
  <results_reference>
    <citation>Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine. 2013 Nov 12;31(47):5531-6. doi: 10.1016/j.vaccine.2013.09.021. Epub 2013 Sep 21.</citation>
    <PMID>24063976</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 15, 2012</study_first_submitted>
  <study_first_submitted_qc>October 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2012</study_first_posted>
  <last_update_submitted>February 20, 2014</last_update_submitted>
  <last_update_submitted_qc>February 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Institute for Public Health and the Environment (RIVM)</investigator_affiliation>
    <investigator_full_name>Pauline Verdijk</investigator_full_name>
    <investigator_title>Clinical Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Inactivated Poliomyelitis Vaccine</keyword>
  <keyword>Polio</keyword>
  <keyword>Sabin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

